Jade Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 06/17/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $93.1M | $53.2M | — | $64.2M | $38.6M |
| Operating expenses | $113.5M | $74.6M | — | $81.4M | $53.2M |
| Operating income | -$113.5M | -$74.6M | — | -$81.4M | -$53.2M |
| Pretax income | -$127.4M | -$69.6M | — | -$75.5M | -$51.5M |
| Income tax expense | $58,000 | $55,000 | — | $56,000 | $25,000 |
| Net income | -$127.4M | -$69.6M | — | -$75.5M | -$51.5M |
| Balance Sheet | |||||
| Cash and equivalents | $88.4M | $69.4M | — | $23.5M | $22.4M |
| Current assets | $348.8M | $69.7M | — | $124.2M | $131.5M |
| Total assets | $349.8M | $72.8M | — | $127.4M | $135.3M |
| Current liabilities | $16.5M | $12.0M | — | $17.6M | $7.8M |
| Total liabilities | $17.3M | $119.6M | — | $18.0M | $8.6M |
| Stockholders' equity | $332.5M | -$46.8M | $1,000 | $109.5M | $126.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$94.7M | -$71.2M | — | -$56.8M | -$39.1M |
| Depreciation and amortization | $26,000 | $282,000 | — | $96,000 | $68,000 |
| Stock-based compensation | $20.0M | $11.3M | — | $11.9M | $5.5M |
| Capital expenditure | $196,000 | — | — | $142,000 | $195,000 |
| Free cash flow | -$94.9M | — | — | -$56.9M | -$39.3M |
| Impairments | — | — | — | $0 | $0 |
Shares outstanding 49.4M · Free float 63.7%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.